-

Verastem Oncology to Participate in the H.C. Wainwright Global Life Sciences Conference

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will participate in the virtual H.C. Wainwright Global Life Sciences Conference. The fireside chat will be made available for on-demand listening beginning Tuesday, March 9, 2021 at 7:00 a.m. EST.

The webcast of the fireside chat will be available on the “Media” section of the Company’s website at www.verastem.com under “Events & Presentations”.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.

Contacts

Verastem Oncology Contacts:

Investors:
Ajay Munshi
Vice President, Corporate Development
+1 781-469-1579
amunshi@verastem.com

Sherri Spear
Argot Partners
+1 212 600 1902
sherri@argotpartners.com

Media:
Lisa Buffington
Corporate Communications
+1 781-292-4205
lbuffington@verastem.com

Industry:

Verastem, Inc.

NASDAQ:VSTM
Release Versions
English

Contacts

Verastem Oncology Contacts:

Investors:
Ajay Munshi
Vice President, Corporate Development
+1 781-469-1579
amunshi@verastem.com

Sherri Spear
Argot Partners
+1 212 600 1902
sherri@argotpartners.com

Media:
Lisa Buffington
Corporate Communications
+1 781-292-4205
lbuffington@verastem.com

More News From Verastem, Inc.

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 399,750 restricted stock units to 30 new employees and the grant of stock options to purchase 91,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment wit...

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

BOSTON--(BUSINESS WIRE)--VS-7375 (investigational KRAS G12D ON/OFF inhibitor) demonstrates clinical activity with a favorable safety profile in TARGET-D 101 clinical trial...

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

BOSTON--(BUSINESS WIRE)--Verastem Oncology announces updated results from RAMP 205 clinical trial in first-line metastatic pancreatic ductal adenocarcinoma...
Back to Newsroom